{
  "ticker": "AMGN",
  "entities": [
    {
      "text": "Amgen Inc.",
      "label": "ORG",
      "start": 0,
      "end": 10,
      "sentence": "Amgen Inc. (NASDAQ:AMGN) shares are trading higher after a series of positive clinical updates, analyst upgrades and bullish research notes.",
      "context": "Amgen Inc. (NASDAQ:AMGN) shares are trading higher after a s",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "AMGN",
      "label": "ORG",
      "start": 19,
      "end": 23,
      "sentence": "Amgen Inc. (NASDAQ:AMGN) shares are trading higher after a series of positive clinical updates, analyst upgrades and bullish research notes.",
      "context": "Amgen Inc. (NASDAQ:AMGN) shares are trading higher after a series of posi",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Amgen",
      "label": "ORG",
      "start": 161,
      "end": 166,
      "sentence": "Positive Sentiment:\nAmgen reported that its Phase 3 trial of etelcalcetide in pediatric kidney patients is progressing, potentially expanding its treatment portfolio in a high-need population.",
      "context": "s and bullish research notes.\nPositive Sentiment:\nAmgen reported that its Phase 3 trial of etelcalcetide",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "3",
      "label": "CARDINAL",
      "start": 191,
      "end": 192,
      "sentence": "Positive Sentiment:\nAmgen reported that its Phase 3 trial of etelcalcetide in pediatric kidney patients is progressing, potentially expanding its treatment portfolio in a high-need population.",
      "context": "Positive Sentiment:\nAmgen reported that its Phase 3 trial of etelcalcetide in pediatric kidney patien",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Amgen",
      "label": "ORG",
      "start": 334,
      "end": 339,
      "sentence": "Amgen’s Phase 3 Study on Etelcalcetide\nPositive Sentiment:",
      "context": "ts treatment portfolio in a high-need population.\nAmgen’s Phase 3 Study on Etelcalcetide\nPositive Sentime",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "William Blair",
      "label": "ORG",
      "start": 393,
      "end": 406,
      "sentence": "William Blair raised its Q2 2025 EPS estimate for AMGN to $5.21 and maintained an “Outperform” rating.",
      "context": "hase 3 Study on Etelcalcetide\nPositive Sentiment:\nWilliam Blair raised its Q2 2025 EPS estimate for AMGN to $5.21",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Q2 2025",
      "label": "DATE",
      "start": 418,
      "end": 425,
      "sentence": "William Blair raised its Q2 2025 EPS estimate for AMGN to $5.21 and maintained an “Outperform” rating.",
      "context": "tide\nPositive Sentiment:\nWilliam Blair raised its Q2 2025 EPS estimate for AMGN to $5.21 and maintained an",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "AMGN",
      "label": "ORG",
      "start": 443,
      "end": 447,
      "sentence": "William Blair raised its Q2 2025 EPS estimate for AMGN to $5.21 and maintained an “Outperform” rating.",
      "context": "William Blair raised its Q2 2025 EPS estimate for AMGN to $5.21 and maintained an “Outperform” rating.\nW",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "5.21",
      "label": "MONEY",
      "start": 452,
      "end": 456,
      "sentence": "William Blair raised its Q2 2025 EPS estimate for AMGN to $5.21 and maintained an “Outperform” rating.",
      "context": "lair raised its Q2 2025 EPS estimate for AMGN to $5.21 and maintained an “Outperform” rating.\nWilliam Bl",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "William Blair",
      "label": "ORG",
      "start": 496,
      "end": 509,
      "sentence": "William Blair Weighs in on Amgen's Q2 Earnings\nPositive Sentiment:",
      "context": "N to $5.21 and maintained an “Outperform” rating.\nWilliam Blair Weighs in on Amgen's Q2 Earnings\nPositive Sentime",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Amgen",
      "label": "ORG",
      "start": 523,
      "end": 528,
      "sentence": "William Blair Weighs in on Amgen's Q2 Earnings\nPositive Sentiment:",
      "context": "n “Outperform” rating.\nWilliam Blair Weighs in on Amgen's Q2 Earnings\nPositive Sentiment:\nWilliam Blair a",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Q2",
      "label": "DATE",
      "start": 531,
      "end": 533,
      "sentence": "William Blair Weighs in on Amgen's Q2 Earnings\nPositive Sentiment:",
      "context": "rform” rating.\nWilliam Blair Weighs in on Amgen's Q2 Earnings\nPositive Sentiment:\nWilliam Blair also b",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "William Blair",
      "label": "ORG",
      "start": 563,
      "end": 576,
      "sentence": "William Blair also boosted its FY 2026 EPS forecast for Amgen to $21.67 while reaffirming an “Outperform” stance.",
      "context": "ghs in on Amgen's Q2 Earnings\nPositive Sentiment:\nWilliam Blair also boosted its FY 2026 EPS forecast for Amgen t",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "FY 2026",
      "label": "DATE",
      "start": 594,
      "end": 601,
      "sentence": "William Blair also boosted its FY 2026 EPS forecast for Amgen to $21.67 while reaffirming an “Outperform” stance.",
      "context": "ositive Sentiment:\nWilliam Blair also boosted its FY 2026 EPS forecast for Amgen to $21.67 while reaffirmin",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Amgen",
      "label": "ORG",
      "start": 619,
      "end": 624,
      "sentence": "William Blair also boosted its FY 2026 EPS forecast for Amgen to $21.67 while reaffirming an “Outperform” stance.",
      "context": "m Blair also boosted its FY 2026 EPS forecast for Amgen to $21.67 while reaffirming an “Outperform” stanc",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "21.67",
      "label": "MONEY",
      "start": 629,
      "end": 634,
      "sentence": "William Blair also boosted its FY 2026 EPS forecast for Amgen to $21.67 while reaffirming an “Outperform” stance.",
      "context": "so boosted its FY 2026 EPS forecast for Amgen to $21.67 while reaffirming an “Outperform” stance.\nWilliam",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "William Blair",
      "label": "ORG",
      "start": 677,
      "end": 690,
      "sentence": "William Blair Has Positive Outlook of Amgen FY2026 Earnings\nPositive Sentiment:",
      "context": "$21.67 while reaffirming an “Outperform” stance.\nWilliam Blair Has Positive Outlook of Amgen FY2026 Earnings\nPos",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Amgen",
      "label": "ORG",
      "start": 715,
      "end": 720,
      "sentence": "William Blair Has Positive Outlook of Amgen FY2026 Earnings\nPositive Sentiment:",
      "context": "rm” stance.\nWilliam Blair Has Positive Outlook of Amgen FY2026 Earnings\nPositive Sentiment:\nZacks upgrade",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "FY2026",
      "label": "DATE",
      "start": 721,
      "end": 727,
      "sentence": "William Blair Has Positive Outlook of Amgen FY2026 Earnings\nPositive Sentiment:",
      "context": "ance.\nWilliam Blair Has Positive Outlook of Amgen FY2026 Earnings\nPositive Sentiment:\nZacks upgraded Amgen",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Zacks",
      "label": "ORG",
      "start": 757,
      "end": 762,
      "sentence": "Zacks upgraded Amgen to a #2 (Buy), citing growing confidence in its earnings trajectory.",
      "context": "look of Amgen FY2026 Earnings\nPositive Sentiment:\nZacks upgraded Amgen to a #2 (Buy), citing growing conf",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Amgen",
      "label": "ORG",
      "start": 772,
      "end": 777,
      "sentence": "Zacks upgraded Amgen to a #2 (Buy), citing growing confidence in its earnings trajectory.",
      "context": "Y2026 Earnings\nPositive Sentiment:\nZacks upgraded Amgen to a #2 (Buy), citing growing confidence in its e",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "2",
      "label": "CARDINAL",
      "start": 784,
      "end": 785,
      "sentence": "Zacks upgraded Amgen to a #2 (Buy), citing growing confidence in its earnings trajectory.",
      "context": "gs\nPositive Sentiment:\nZacks upgraded Amgen to a #2 (Buy), citing growing confidence in its earnings",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Amgen",
      "label": "ORG",
      "start": 858,
      "end": 863,
      "sentence": "What Makes Amgen (AMGN) a New Buy Stock\nPositive Sentiment:",
      "context": "confidence in its earnings trajectory.\nWhat Makes Amgen (AMGN) a New Buy Stock\nPositive Sentiment:\nSeekin",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "AMGN",
      "label": "ORG",
      "start": 865,
      "end": 869,
      "sentence": "What Makes Amgen (AMGN) a New Buy Stock\nPositive Sentiment:",
      "context": "nce in its earnings trajectory.\nWhat Makes Amgen (AMGN) a New Buy Stock\nPositive Sentiment:\nSeeking Alph",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Seeking Alpha",
      "label": "ORG",
      "start": 907,
      "end": 920,
      "sentence": "Seeking Alpha notes Amgen’s expanding biosimilars and rare disease pipeline as critical growth drivers to offset upcoming patent expiries.",
      "context": "Amgen (AMGN) a New Buy Stock\nPositive Sentiment:\nSeeking Alpha notes Amgen’s expanding biosimilars and rare dise",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Amgen",
      "label": "ORG",
      "start": 927,
      "end": 932,
      "sentence": "Seeking Alpha notes Amgen’s expanding biosimilars and rare disease pipeline as critical growth drivers to offset upcoming patent expiries.",
      "context": "Buy Stock\nPositive Sentiment:\nSeeking Alpha notes Amgen’s expanding biosimilars and rare disease pipeline",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Amgen",
      "label": "ORG",
      "start": 1046,
      "end": 1051,
      "sentence": "Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns\nPositive Sentiment:",
      "context": "rowth drivers to offset upcoming patent expiries.\nAmgen: Biosimilars And Rare Disease Pipeline Crucial To",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Seeking Alpha",
      "label": "ORG",
      "start": 1161,
      "end": 1174,
      "sentence": "Another Seeking Alpha piece highlights Amgen’s attractive starting dividend yield as a “wealth compounder.”",
      "context": "Patent Cliff Concerns\nPositive Sentiment:\nAnother Seeking Alpha piece highlights Amgen’s attractive starting divi",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Amgen",
      "label": "ORG",
      "start": 1192,
      "end": 1197,
      "sentence": "Another Seeking Alpha piece highlights Amgen’s attractive starting dividend yield as a “wealth compounder.”",
      "context": "Sentiment:\nAnother Seeking Alpha piece highlights Amgen’s attractive starting dividend yield as a “wealth",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Amgen",
      "label": "ORG",
      "start": 1261,
      "end": 1266,
      "sentence": "Amgen: Great Starting Yield For This Wealth Compounder\nNeutral Sentiment:",
      "context": "starting dividend yield as a “wealth compounder.”\nAmgen: Great Starting Yield For This Wealth Compounder",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "MSN",
      "label": "ORG",
      "start": 1358,
      "end": 1361,
      "sentence": "An earnings preview on MSN outlines expectations for the upcoming Q2 report without major revisions.",
      "context": "pounder\nNeutral Sentiment:\nAn earnings preview on MSN outlines expectations for the upcoming Q2 report",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Q2",
      "label": "DATE",
      "start": 1401,
      "end": 1403,
      "sentence": "An earnings preview on MSN outlines expectations for the upcoming Q2 report without major revisions.",
      "context": "iew on MSN outlines expectations for the upcoming Q2 report without major revisions.\nEarnings Preview:",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Amgen",
      "label": "ORG",
      "start": 1474,
      "end": 1479,
      "sentence": "Earnings Preview: What to Expect From Amgen’s Report\nNeutral Sentiment:",
      "context": "revisions.\nEarnings Preview: What to Expect From Amgen’s Report\nNeutral Sentiment:\nZacks compares Amgen’",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Zacks",
      "label": "ORG",
      "start": 1508,
      "end": 1513,
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "context": "to Expect From Amgen’s Report\nNeutral Sentiment:\nZacks compares Amgen’s year-to-date performance to sect",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Amgen",
      "label": "ORG",
      "start": 1523,
      "end": 1528,
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "context": "Amgen’s Report\nNeutral Sentiment:\nZacks compares Amgen’s year-to-date performance to sector peers, notin",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "year-to-date",
      "label": "DATE",
      "start": 1531,
      "end": 1543,
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "context": "Report\nNeutral Sentiment:\nZacks compares Amgen’s year-to-date performance to sector peers, noting it has been r",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Amgen",
      "label": "ORG",
      "start": 1656,
      "end": 1661,
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "context": "e with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:\nZacks flags",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "AMGN",
      "label": "ORG",
      "start": 1663,
      "end": 1667,
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "context": "medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:\nZacks flags height",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "This Year",
      "label": "DATE",
      "start": 1669,
      "end": 1678,
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "context": "l stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:\nZacks flags heightened user i",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Zacks",
      "label": "ORG",
      "start": 1699,
      "end": 1704,
      "sentence": "Zacks flags heightened user interest in AMGN, advising investors to weigh key facts before making a move.",
      "context": "agging Amgen (AMGN) This Year?\nNeutral Sentiment:\nZacks flags heightened user interest in AMGN, advising",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "AMGN",
      "label": "ORG",
      "start": 1739,
      "end": 1743,
      "sentence": "Zacks flags heightened user interest in AMGN, advising investors to weigh key facts before making a move.",
      "context": "entiment:\nZacks flags heightened user interest in AMGN, advising investors to weigh key facts before mak",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Amgen Inc.",
      "label": "ORG",
      "start": 1805,
      "end": 1815,
      "sentence": "Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It",
      "context": "nvestors to weigh key facts before making a move.\nAmgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "AMGN",
      "label": "ORG",
      "start": 1817,
      "end": 1821,
      "sentence": "Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It",
      "context": "weigh key facts before making a move.\nAmgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Bettin",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "2h ago",
      "label": "DATE",
      "start": 1886,
      "end": 1892,
      "sentence": "Posted 2h ago\nAI Generated.",
      "context": "Stock: Facts to Know Before Betting on It\nPosted 2h ago\nAI Generated. May Contain Errors.",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "AI Generated",
      "label": "ORG",
      "start": 1893,
      "end": 1905,
      "sentence": "Posted 2h ago\nAI Generated.",
      "context": "Facts to Know Before Betting on It\nPosted 2h ago\nAI Generated. May Contain Errors.",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    }
  ],
  "relationships": [
    {
      "type": "SVO",
      "subject": "Blair",
      "verb": "raised",
      "object": "estimate",
      "sentence": "William Blair raised its Q2 2025 EPS estimate for AMGN to $5.21 and maintained an “Outperform” rating.",
      "importance": 9
    },
    {
      "type": "SVO",
      "subject": "Blair",
      "verb": "Weighs",
      "object": "Sentiment",
      "sentence": "William Blair Weighs in on Amgen's Q2 Earnings\nPositive Sentiment:",
      "importance": 5
    },
    {
      "type": "SVO",
      "subject": "Blair",
      "verb": "boosted",
      "object": "forecast",
      "sentence": "William Blair also boosted its FY 2026 EPS forecast for Amgen to $21.67 while reaffirming an “Outperform” stance.",
      "importance": 8
    },
    {
      "type": "SVO",
      "subject": "Blair",
      "verb": "Has",
      "object": "Outlook",
      "sentence": "William Blair Has Positive Outlook of Amgen FY2026 Earnings\nPositive Sentiment:",
      "importance": 6
    },
    {
      "type": "SVO",
      "subject": "Zacks",
      "verb": "upgraded",
      "object": "Amgen",
      "sentence": "Zacks upgraded Amgen to a #2 (Buy), citing growing confidence in its earnings trajectory.",
      "importance": 5
    },
    {
      "type": "SVO",
      "subject": "What",
      "verb": "Makes",
      "object": "Sentiment",
      "sentence": "What Makes Amgen (AMGN) a New Buy Stock\nPositive Sentiment:",
      "importance": 4
    },
    {
      "type": "SVO",
      "subject": "Alpha",
      "verb": "notes",
      "object": "biosimilars",
      "sentence": "Seeking Alpha notes Amgen’s expanding biosimilars and rare disease pipeline as critical growth drivers to offset upcoming patent expiries.",
      "importance": 5
    },
    {
      "type": "SVO",
      "subject": "piece",
      "verb": "highlights",
      "object": "yield",
      "sentence": "Another Seeking Alpha piece highlights Amgen’s attractive starting dividend yield as a “wealth compounder.”",
      "importance": 5
    },
    {
      "type": "SVO",
      "subject": "preview",
      "verb": "outlines",
      "object": "expectations",
      "sentence": "An earnings preview on MSN outlines expectations for the upcoming Q2 report without major revisions.",
      "importance": 3
    },
    {
      "type": "SVO",
      "subject": "Zacks",
      "verb": "compares",
      "object": "performance",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "importance": 13
    },
    {
      "type": "SVO",
      "subject": "Stocks",
      "verb": "Lagging",
      "object": "Amgen",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "importance": 13
    },
    {
      "type": "SVO",
      "subject": "Zacks",
      "verb": "flags",
      "object": "interest",
      "sentence": "Zacks flags heightened user interest in AMGN, advising investors to weigh key facts before making a move.",
      "importance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "Amgen",
      "entity1_type": "ORG",
      "entity2": "Inc.",
      "entity2_type": "ORG",
      "sentence": "Amgen Inc. (NASDAQ:AMGN) shares are trading higher after a series of positive clinical updates, analyst upgrades and bullish research notes.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Amgen",
      "entity1_type": "ORG",
      "entity2": "AMGN",
      "entity2_type": "ORG",
      "sentence": "Amgen Inc. (NASDAQ:AMGN) shares are trading higher after a series of positive clinical updates, analyst upgrades and bullish research notes.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "Inc.",
      "entity1_type": "ORG",
      "entity2": "AMGN",
      "entity2_type": "ORG",
      "sentence": "Amgen Inc. (NASDAQ:AMGN) shares are trading higher after a series of positive clinical updates, analyst upgrades and bullish research notes.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Amgen",
      "entity1_type": "ORG",
      "entity2": "3",
      "entity2_type": "CARDINAL",
      "sentence": "Positive Sentiment:\nAmgen reported that its Phase 3 trial of etelcalcetide in pediatric kidney patients is progressing, potentially expanding its treatment portfolio in a high-need population.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "ORG",
      "entity2": "Blair",
      "entity2_type": "ORG",
      "sentence": "William Blair raised its Q2 2025 EPS estimate for AMGN to $5.21 and maintained an “Outperform” rating.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "William Blair raised its Q2 2025 EPS estimate for AMGN to $5.21 and maintained an “Outperform” rating.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "ORG",
      "entity2": "2025",
      "entity2_type": "DATE",
      "sentence": "William Blair raised its Q2 2025 EPS estimate for AMGN to $5.21 and maintained an “Outperform” rating.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "ORG",
      "entity2": "AMGN",
      "entity2_type": "ORG",
      "sentence": "William Blair raised its Q2 2025 EPS estimate for AMGN to $5.21 and maintained an “Outperform” rating.",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "ORG",
      "entity2": "5.21",
      "entity2_type": "MONEY",
      "sentence": "William Blair raised its Q2 2025 EPS estimate for AMGN to $5.21 and maintained an “Outperform” rating.",
      "distance": 12
    },
    {
      "type": "co-occurrence",
      "entity1": "Blair",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "William Blair raised its Q2 2025 EPS estimate for AMGN to $5.21 and maintained an “Outperform” rating.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "Blair",
      "entity1_type": "ORG",
      "entity2": "2025",
      "entity2_type": "DATE",
      "sentence": "William Blair raised its Q2 2025 EPS estimate for AMGN to $5.21 and maintained an “Outperform” rating.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Blair",
      "entity1_type": "ORG",
      "entity2": "AMGN",
      "entity2_type": "ORG",
      "sentence": "William Blair raised its Q2 2025 EPS estimate for AMGN to $5.21 and maintained an “Outperform” rating.",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "Blair",
      "entity1_type": "ORG",
      "entity2": "5.21",
      "entity2_type": "MONEY",
      "sentence": "William Blair raised its Q2 2025 EPS estimate for AMGN to $5.21 and maintained an “Outperform” rating.",
      "distance": 11
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "2025",
      "entity2_type": "DATE",
      "sentence": "William Blair raised its Q2 2025 EPS estimate for AMGN to $5.21 and maintained an “Outperform” rating.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "AMGN",
      "entity2_type": "ORG",
      "sentence": "William Blair raised its Q2 2025 EPS estimate for AMGN to $5.21 and maintained an “Outperform” rating.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "5.21",
      "entity2_type": "MONEY",
      "sentence": "William Blair raised its Q2 2025 EPS estimate for AMGN to $5.21 and maintained an “Outperform” rating.",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "2025",
      "entity1_type": "DATE",
      "entity2": "AMGN",
      "entity2_type": "ORG",
      "sentence": "William Blair raised its Q2 2025 EPS estimate for AMGN to $5.21 and maintained an “Outperform” rating.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "2025",
      "entity1_type": "DATE",
      "entity2": "5.21",
      "entity2_type": "MONEY",
      "sentence": "William Blair raised its Q2 2025 EPS estimate for AMGN to $5.21 and maintained an “Outperform” rating.",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "AMGN",
      "entity1_type": "ORG",
      "entity2": "5.21",
      "entity2_type": "MONEY",
      "sentence": "William Blair raised its Q2 2025 EPS estimate for AMGN to $5.21 and maintained an “Outperform” rating.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "ORG",
      "entity2": "Blair",
      "entity2_type": "ORG",
      "sentence": "William Blair Weighs in on Amgen's Q2 Earnings\nPositive Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "ORG",
      "entity2": "Amgen",
      "entity2_type": "ORG",
      "sentence": "William Blair Weighs in on Amgen's Q2 Earnings\nPositive Sentiment:",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "William Blair Weighs in on Amgen's Q2 Earnings\nPositive Sentiment:",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Blair",
      "entity1_type": "ORG",
      "entity2": "Amgen",
      "entity2_type": "ORG",
      "sentence": "William Blair Weighs in on Amgen's Q2 Earnings\nPositive Sentiment:",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Blair",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "William Blair Weighs in on Amgen's Q2 Earnings\nPositive Sentiment:",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "Amgen",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "William Blair Weighs in on Amgen's Q2 Earnings\nPositive Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "ORG",
      "entity2": "Blair",
      "entity2_type": "ORG",
      "sentence": "William Blair also boosted its FY 2026 EPS forecast for Amgen to $21.67 while reaffirming an “Outperform” stance.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "ORG",
      "entity2": "FY",
      "entity2_type": "DATE",
      "sentence": "William Blair also boosted its FY 2026 EPS forecast for Amgen to $21.67 while reaffirming an “Outperform” stance.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "ORG",
      "entity2": "2026",
      "entity2_type": "DATE",
      "sentence": "William Blair also boosted its FY 2026 EPS forecast for Amgen to $21.67 while reaffirming an “Outperform” stance.",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "ORG",
      "entity2": "Amgen",
      "entity2_type": "ORG",
      "sentence": "William Blair also boosted its FY 2026 EPS forecast for Amgen to $21.67 while reaffirming an “Outperform” stance.",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "ORG",
      "entity2": "21.67",
      "entity2_type": "MONEY",
      "sentence": "William Blair also boosted its FY 2026 EPS forecast for Amgen to $21.67 while reaffirming an “Outperform” stance.",
      "distance": 13
    },
    {
      "type": "co-occurrence",
      "entity1": "Blair",
      "entity1_type": "ORG",
      "entity2": "FY",
      "entity2_type": "DATE",
      "sentence": "William Blair also boosted its FY 2026 EPS forecast for Amgen to $21.67 while reaffirming an “Outperform” stance.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Blair",
      "entity1_type": "ORG",
      "entity2": "2026",
      "entity2_type": "DATE",
      "sentence": "William Blair also boosted its FY 2026 EPS forecast for Amgen to $21.67 while reaffirming an “Outperform” stance.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "Blair",
      "entity1_type": "ORG",
      "entity2": "Amgen",
      "entity2_type": "ORG",
      "sentence": "William Blair also boosted its FY 2026 EPS forecast for Amgen to $21.67 while reaffirming an “Outperform” stance.",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "Blair",
      "entity1_type": "ORG",
      "entity2": "21.67",
      "entity2_type": "MONEY",
      "sentence": "William Blair also boosted its FY 2026 EPS forecast for Amgen to $21.67 while reaffirming an “Outperform” stance.",
      "distance": 12
    },
    {
      "type": "co-occurrence",
      "entity1": "FY",
      "entity1_type": "DATE",
      "entity2": "2026",
      "entity2_type": "DATE",
      "sentence": "William Blair also boosted its FY 2026 EPS forecast for Amgen to $21.67 while reaffirming an “Outperform” stance.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "FY",
      "entity1_type": "DATE",
      "entity2": "Amgen",
      "entity2_type": "ORG",
      "sentence": "William Blair also boosted its FY 2026 EPS forecast for Amgen to $21.67 while reaffirming an “Outperform” stance.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "FY",
      "entity1_type": "DATE",
      "entity2": "21.67",
      "entity2_type": "MONEY",
      "sentence": "William Blair also boosted its FY 2026 EPS forecast for Amgen to $21.67 while reaffirming an “Outperform” stance.",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "2026",
      "entity1_type": "DATE",
      "entity2": "Amgen",
      "entity2_type": "ORG",
      "sentence": "William Blair also boosted its FY 2026 EPS forecast for Amgen to $21.67 while reaffirming an “Outperform” stance.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "2026",
      "entity1_type": "DATE",
      "entity2": "21.67",
      "entity2_type": "MONEY",
      "sentence": "William Blair also boosted its FY 2026 EPS forecast for Amgen to $21.67 while reaffirming an “Outperform” stance.",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Amgen",
      "entity1_type": "ORG",
      "entity2": "21.67",
      "entity2_type": "MONEY",
      "sentence": "William Blair also boosted its FY 2026 EPS forecast for Amgen to $21.67 while reaffirming an “Outperform” stance.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "ORG",
      "entity2": "Blair",
      "entity2_type": "ORG",
      "sentence": "William Blair Has Positive Outlook of Amgen FY2026 Earnings\nPositive Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "ORG",
      "entity2": "Amgen",
      "entity2_type": "ORG",
      "sentence": "William Blair Has Positive Outlook of Amgen FY2026 Earnings\nPositive Sentiment:",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "William",
      "entity1_type": "ORG",
      "entity2": "FY2026",
      "entity2_type": "DATE",
      "sentence": "William Blair Has Positive Outlook of Amgen FY2026 Earnings\nPositive Sentiment:",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Blair",
      "entity1_type": "ORG",
      "entity2": "Amgen",
      "entity2_type": "ORG",
      "sentence": "William Blair Has Positive Outlook of Amgen FY2026 Earnings\nPositive Sentiment:",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "Blair",
      "entity1_type": "ORG",
      "entity2": "FY2026",
      "entity2_type": "DATE",
      "sentence": "William Blair Has Positive Outlook of Amgen FY2026 Earnings\nPositive Sentiment:",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "Amgen",
      "entity1_type": "ORG",
      "entity2": "FY2026",
      "entity2_type": "DATE",
      "sentence": "William Blair Has Positive Outlook of Amgen FY2026 Earnings\nPositive Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Zacks",
      "entity1_type": "ORG",
      "entity2": "Amgen",
      "entity2_type": "ORG",
      "sentence": "Zacks upgraded Amgen to a #2 (Buy), citing growing confidence in its earnings trajectory.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Zacks",
      "entity1_type": "ORG",
      "entity2": "2",
      "entity2_type": "CARDINAL",
      "sentence": "Zacks upgraded Amgen to a #2 (Buy), citing growing confidence in its earnings trajectory.",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "Amgen",
      "entity1_type": "ORG",
      "entity2": "2",
      "entity2_type": "CARDINAL",
      "sentence": "Zacks upgraded Amgen to a #2 (Buy), citing growing confidence in its earnings trajectory.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Amgen",
      "entity1_type": "ORG",
      "entity2": "AMGN",
      "entity2_type": "ORG",
      "sentence": "What Makes Amgen (AMGN) a New Buy Stock\nPositive Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Seeking",
      "entity1_type": "ORG",
      "entity2": "Alpha",
      "entity2_type": "ORG",
      "sentence": "Seeking Alpha notes Amgen’s expanding biosimilars and rare disease pipeline as critical growth drivers to offset upcoming patent expiries.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Seeking",
      "entity1_type": "ORG",
      "entity2": "Amgen",
      "entity2_type": "ORG",
      "sentence": "Seeking Alpha notes Amgen’s expanding biosimilars and rare disease pipeline as critical growth drivers to offset upcoming patent expiries.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "Alpha",
      "entity1_type": "ORG",
      "entity2": "Amgen",
      "entity2_type": "ORG",
      "sentence": "Seeking Alpha notes Amgen’s expanding biosimilars and rare disease pipeline as critical growth drivers to offset upcoming patent expiries.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Seeking",
      "entity1_type": "ORG",
      "entity2": "Alpha",
      "entity2_type": "ORG",
      "sentence": "Another Seeking Alpha piece highlights Amgen’s attractive starting dividend yield as a “wealth compounder.”",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Seeking",
      "entity1_type": "ORG",
      "entity2": "Amgen",
      "entity2_type": "ORG",
      "sentence": "Another Seeking Alpha piece highlights Amgen’s attractive starting dividend yield as a “wealth compounder.”",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Alpha",
      "entity1_type": "ORG",
      "entity2": "Amgen",
      "entity2_type": "ORG",
      "sentence": "Another Seeking Alpha piece highlights Amgen’s attractive starting dividend yield as a “wealth compounder.”",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "MSN",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "An earnings preview on MSN outlines expectations for the upcoming Q2 report without major revisions.",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "Zacks",
      "entity1_type": "ORG",
      "entity2": "Amgen",
      "entity2_type": "ORG",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Zacks",
      "entity1_type": "ORG",
      "entity2": "year",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Zacks",
      "entity1_type": "ORG",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "Zacks",
      "entity1_type": "ORG",
      "entity2": "to",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "Zacks",
      "entity1_type": "ORG",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Zacks",
      "entity1_type": "ORG",
      "entity2": "date",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "Zacks",
      "entity1_type": "ORG",
      "entity2": "Amgen",
      "entity2_type": "ORG",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 30
    },
    {
      "type": "co-occurrence",
      "entity1": "Zacks",
      "entity1_type": "ORG",
      "entity2": "AMGN",
      "entity2_type": "ORG",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 32
    },
    {
      "type": "co-occurrence",
      "entity1": "Zacks",
      "entity1_type": "ORG",
      "entity2": "This",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 34
    },
    {
      "type": "co-occurrence",
      "entity1": "Zacks",
      "entity1_type": "ORG",
      "entity2": "Year",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 35
    },
    {
      "type": "co-occurrence",
      "entity1": "Amgen",
      "entity1_type": "ORG",
      "entity2": "year",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Amgen",
      "entity1_type": "ORG",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "Amgen",
      "entity1_type": "ORG",
      "entity2": "to",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Amgen",
      "entity1_type": "ORG",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "Amgen",
      "entity1_type": "ORG",
      "entity2": "date",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "Amgen",
      "entity1_type": "ORG",
      "entity2": "Amgen",
      "entity2_type": "ORG",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 28
    },
    {
      "type": "co-occurrence",
      "entity1": "Amgen",
      "entity1_type": "ORG",
      "entity2": "AMGN",
      "entity2_type": "ORG",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 30
    },
    {
      "type": "co-occurrence",
      "entity1": "Amgen",
      "entity1_type": "ORG",
      "entity2": "This",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 32
    },
    {
      "type": "co-occurrence",
      "entity1": "Amgen",
      "entity1_type": "ORG",
      "entity2": "Year",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 33
    },
    {
      "type": "co-occurrence",
      "entity1": "year",
      "entity1_type": "DATE",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "year",
      "entity1_type": "DATE",
      "entity2": "to",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "year",
      "entity1_type": "DATE",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "year",
      "entity1_type": "DATE",
      "entity2": "date",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "year",
      "entity1_type": "DATE",
      "entity2": "Amgen",
      "entity2_type": "ORG",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 26
    },
    {
      "type": "co-occurrence",
      "entity1": "year",
      "entity1_type": "DATE",
      "entity2": "AMGN",
      "entity2_type": "ORG",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 28
    },
    {
      "type": "co-occurrence",
      "entity1": "year",
      "entity1_type": "DATE",
      "entity2": "This",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 30
    },
    {
      "type": "co-occurrence",
      "entity1": "year",
      "entity1_type": "DATE",
      "entity2": "Year",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 31
    },
    {
      "type": "co-occurrence",
      "entity1": "-",
      "entity1_type": "DATE",
      "entity2": "to",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "-",
      "entity1_type": "DATE",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "-",
      "entity1_type": "DATE",
      "entity2": "date",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "-",
      "entity1_type": "DATE",
      "entity2": "Amgen",
      "entity2_type": "ORG",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 25
    },
    {
      "type": "co-occurrence",
      "entity1": "-",
      "entity1_type": "DATE",
      "entity2": "AMGN",
      "entity2_type": "ORG",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 27
    },
    {
      "type": "co-occurrence",
      "entity1": "-",
      "entity1_type": "DATE",
      "entity2": "This",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 29
    },
    {
      "type": "co-occurrence",
      "entity1": "-",
      "entity1_type": "DATE",
      "entity2": "Year",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 30
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "DATE",
      "entity2": "-",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "DATE",
      "entity2": "date",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "DATE",
      "entity2": "Amgen",
      "entity2_type": "ORG",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 24
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "DATE",
      "entity2": "AMGN",
      "entity2_type": "ORG",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 26
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "DATE",
      "entity2": "This",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 28
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "DATE",
      "entity2": "Year",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 29
    },
    {
      "type": "co-occurrence",
      "entity1": "-",
      "entity1_type": "DATE",
      "entity2": "date",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "-",
      "entity1_type": "DATE",
      "entity2": "Amgen",
      "entity2_type": "ORG",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 23
    },
    {
      "type": "co-occurrence",
      "entity1": "-",
      "entity1_type": "DATE",
      "entity2": "AMGN",
      "entity2_type": "ORG",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 25
    },
    {
      "type": "co-occurrence",
      "entity1": "-",
      "entity1_type": "DATE",
      "entity2": "This",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 27
    },
    {
      "type": "co-occurrence",
      "entity1": "-",
      "entity1_type": "DATE",
      "entity2": "Year",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 28
    },
    {
      "type": "co-occurrence",
      "entity1": "date",
      "entity1_type": "DATE",
      "entity2": "Amgen",
      "entity2_type": "ORG",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 22
    },
    {
      "type": "co-occurrence",
      "entity1": "date",
      "entity1_type": "DATE",
      "entity2": "AMGN",
      "entity2_type": "ORG",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 24
    },
    {
      "type": "co-occurrence",
      "entity1": "date",
      "entity1_type": "DATE",
      "entity2": "This",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 26
    },
    {
      "type": "co-occurrence",
      "entity1": "date",
      "entity1_type": "DATE",
      "entity2": "Year",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 27
    },
    {
      "type": "co-occurrence",
      "entity1": "Amgen",
      "entity1_type": "ORG",
      "entity2": "AMGN",
      "entity2_type": "ORG",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Amgen",
      "entity1_type": "ORG",
      "entity2": "This",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Amgen",
      "entity1_type": "ORG",
      "entity2": "Year",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "AMGN",
      "entity1_type": "ORG",
      "entity2": "This",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "AMGN",
      "entity1_type": "ORG",
      "entity2": "Year",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "This",
      "entity1_type": "DATE",
      "entity2": "Year",
      "entity2_type": "DATE",
      "sentence": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Zacks",
      "entity1_type": "ORG",
      "entity2": "AMGN",
      "entity2_type": "ORG",
      "sentence": "Zacks flags heightened user interest in AMGN, advising investors to weigh key facts before making a move.",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "Amgen",
      "entity1_type": "ORG",
      "entity2": "Inc.",
      "entity2_type": "ORG",
      "sentence": "Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Amgen",
      "entity1_type": "ORG",
      "entity2": "AMGN",
      "entity2_type": "ORG",
      "sentence": "Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "Inc.",
      "entity1_type": "ORG",
      "entity2": "AMGN",
      "entity2_type": "ORG",
      "sentence": "Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "2h",
      "entity1_type": "DATE",
      "entity2": "ago",
      "entity2_type": "DATE",
      "sentence": "Posted 2h ago\nAI Generated.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "2h",
      "entity1_type": "DATE",
      "entity2": "AI",
      "entity2_type": "ORG",
      "sentence": "Posted 2h ago\nAI Generated.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "2h",
      "entity1_type": "DATE",
      "entity2": "Generated",
      "entity2_type": "ORG",
      "sentence": "Posted 2h ago\nAI Generated.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "ago",
      "entity1_type": "DATE",
      "entity2": "AI",
      "entity2_type": "ORG",
      "sentence": "Posted 2h ago\nAI Generated.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "ago",
      "entity1_type": "DATE",
      "entity2": "Generated",
      "entity2_type": "ORG",
      "sentence": "Posted 2h ago\nAI Generated.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "AI",
      "entity1_type": "ORG",
      "entity2": "Generated",
      "entity2_type": "ORG",
      "sentence": "Posted 2h ago\nAI Generated.",
      "distance": 1
    }
  ],
  "key_phrases": [
    {
      "text": "a series",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "positive clinical updates",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "analyst upgrades",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "bullish research notes",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Positive Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "its Phase 3 trial",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "pediatric kidney patients",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "its treatment portfolio",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "a high-need population",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Amgen’s Phase 3 Study",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Positive Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "William Blair",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "its Q2 2025 EPS estimate",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "an “Outperform” rating",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "William Blair",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Amgen's Q2 Earnings",
      "type": "noun_chunk",
      "category": "financial_metric"
    },
    {
      "text": "Positive Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "William Blair",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "its FY 2026 EPS forecast",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "an “Outperform” stance",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "William Blair",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Positive Outlook",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Positive Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "a #",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "growing confidence",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "its earnings trajectory",
      "type": "noun_chunk",
      "category": "financial_metric"
    },
    {
      "text": "Positive Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Seeking Alpha",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Amgen’s expanding biosimilars",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "rare disease pipeline",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "critical growth drivers",
      "type": "noun_chunk",
      "category": "trend"
    },
    {
      "text": "upcoming patent expiries",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Rare Disease Pipeline",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Patent Cliff Concerns",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Positive Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Another Seeking Alpha piece",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Amgen’s attractive starting dividend yield",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "a “wealth compounder",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Great Starting Yield",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "This Wealth Compounder",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Neutral Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "An earnings preview",
      "type": "noun_chunk",
      "category": "financial_metric"
    },
    {
      "text": "the upcoming Q2 report",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "major revisions",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Earnings Preview",
      "type": "noun_chunk",
      "category": "financial_metric"
    },
    {
      "text": "Amgen’s Report",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Neutral Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "sector peers",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "medical stocks",
      "type": "noun_chunk",
      "category": "market_term"
    },
    {
      "text": "Medical Stocks",
      "type": "noun_chunk",
      "category": "market_term"
    },
    {
      "text": "Neutral Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "heightened user interest",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "key facts",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "a move",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Amgen Inc.",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "a Trending Stock",
      "type": "noun_chunk",
      "category": "market_term"
    },
    {
      "text": "$5.21",
      "type": "pattern",
      "category": "money"
    },
    {
      "text": "$21.67",
      "type": "pattern",
      "category": "money"
    },
    {
      "text": "Q2 2025",
      "type": "pattern",
      "category": "quarter"
    },
    {
      "text": "FY2026",
      "type": "pattern",
      "category": "fiscal_year"
    },
    {
      "text": "Earnings",
      "type": "pattern",
      "category": "financial_metric"
    },
    {
      "text": "Earnings",
      "type": "pattern",
      "category": "financial_metric"
    },
    {
      "text": "earnings",
      "type": "pattern",
      "category": "financial_metric"
    },
    {
      "text": "growth",
      "type": "pattern",
      "category": "financial_metric"
    },
    {
      "text": "earnings",
      "type": "pattern",
      "category": "financial_metric"
    },
    {
      "text": "Earnings",
      "type": "pattern",
      "category": "financial_metric"
    },
    {
      "text": "trading",
      "type": "pattern",
      "category": "market_term"
    },
    {
      "text": "Stock",
      "type": "pattern",
      "category": "market_term"
    },
    {
      "text": "Stock",
      "type": "pattern",
      "category": "market_term"
    }
  ],
  "important_sentences": [
    {
      "text": "Zacks compares Amgen’s year-to-date performance to sector peers, noting it has been roughly in line with medical stocks.\nAre Medical Stocks Lagging Amgen (AMGN) This Year?\nNeutral Sentiment:",
      "importance_score": 44,
      "entity_count": 11,
      "financial_keyword_count": 2,
      "money_count": 0,
      "company_count": 4,
      "sentiment": "neutral"
    },
    {
      "text": "William Blair raised its Q2 2025 EPS estimate for AMGN to $5.21 and maintained an “Outperform” rating.",
      "importance_score": 34,
      "entity_count": 6,
      "financial_keyword_count": 3,
      "money_count": 1,
      "company_count": 2,
      "sentiment": "neutral"
    },
    {
      "text": "William Blair also boosted its FY 2026 EPS forecast for Amgen to $21.67 while reaffirming an “Outperform” stance.",
      "importance_score": 31,
      "entity_count": 6,
      "financial_keyword_count": 2,
      "money_count": 1,
      "company_count": 2,
      "sentiment": "neutral"
    },
    {
      "text": "William Blair Has Positive Outlook of Amgen FY2026 Earnings\nPositive Sentiment:",
      "importance_score": 22,
      "entity_count": 4,
      "financial_keyword_count": 2,
      "money_count": 0,
      "company_count": 2,
      "sentiment": "positive"
    },
    {
      "text": "Amgen Inc. (NASDAQ:AMGN) shares are trading higher after a series of positive clinical updates, analyst upgrades and bullish research notes.",
      "importance_score": 20,
      "entity_count": 3,
      "financial_keyword_count": 2,
      "money_count": 0,
      "company_count": 2,
      "sentiment": "positive"
    },
    {
      "text": "Zacks upgraded Amgen to a #2 (Buy), citing growing confidence in its earnings trajectory.",
      "importance_score": 20,
      "entity_count": 3,
      "financial_keyword_count": 2,
      "money_count": 0,
      "company_count": 2,
      "sentiment": "neutral"
    },
    {
      "text": "Seeking Alpha notes Amgen’s expanding biosimilars and rare disease pipeline as critical growth drivers to offset upcoming patent expiries.",
      "importance_score": 20,
      "entity_count": 3,
      "financial_keyword_count": 2,
      "money_count": 0,
      "company_count": 2,
      "sentiment": "positive"
    },
    {
      "text": "Another Seeking Alpha piece highlights Amgen’s attractive starting dividend yield as a “wealth compounder.”",
      "importance_score": 20,
      "entity_count": 3,
      "financial_keyword_count": 2,
      "money_count": 0,
      "company_count": 2,
      "sentiment": "neutral"
    },
    {
      "text": "William Blair Weighs in on Amgen's Q2 Earnings\nPositive Sentiment:",
      "importance_score": 19,
      "entity_count": 4,
      "financial_keyword_count": 1,
      "money_count": 0,
      "company_count": 2,
      "sentiment": "positive"
    },
    {
      "text": "What Makes Amgen (AMGN) a New Buy Stock\nPositive Sentiment:",
      "importance_score": 18,
      "entity_count": 2,
      "financial_keyword_count": 2,
      "money_count": 0,
      "company_count": 2,
      "sentiment": "positive"
    }
  ],
  "entity_statistics": {
    "total_entities": 45,
    "unique_entities": 19,
    "type_counts": {
      "ORG": 33,
      "CARDINAL": 2,
      "DATE": 8,
      "MONEY": 2
    },
    "type_distribution": {
      "ORG": 0.7333333333333333,
      "CARDINAL": 0.044444444444444446,
      "DATE": 0.17777777777777778,
      "MONEY": 0.044444444444444446
    },
    "most_common_entities": [
      [
        "Amgen",
        14
      ],
      [
        "AMGN",
        6
      ],
      [
        "William Blair",
        4
      ],
      [
        "Zacks",
        3
      ],
      [
        "Amgen Inc.",
        2
      ],
      [
        "Q2",
        2
      ],
      [
        "Seeking Alpha",
        2
      ],
      [
        "3",
        1
      ],
      [
        "Q2 2025",
        1
      ],
      [
        "5.21",
        1
      ]
    ],
    "entity_types_found": [
      "ORG",
      "CARDINAL",
      "DATE",
      "MONEY"
    ],
    "company_entities": 33,
    "person_entities": 0,
    "financial_entities": 2,
    "entity_density": 0.16483516483516483
  },
  "financial_analysis": {
    "money_amounts": [
      "5.21",
      "21.67"
    ],
    "percentages": [],
    "companies": [
      "Amgen Inc.",
      "AMGN",
      "Amgen",
      "Amgen",
      "William Blair",
      "AMGN",
      "William Blair",
      "Amgen",
      "William Blair",
      "Amgen",
      "William Blair",
      "Amgen",
      "Zacks",
      "Amgen",
      "Amgen",
      "AMGN",
      "Seeking Alpha",
      "Amgen",
      "Amgen",
      "Seeking Alpha",
      "Amgen",
      "Amgen",
      "MSN",
      "Amgen",
      "Zacks",
      "Amgen",
      "Amgen",
      "AMGN",
      "Zacks",
      "AMGN",
      "Amgen Inc.",
      "AMGN",
      "AI Generated"
    ],
    "people": [],
    "dates": [
      "Q2 2025",
      "Q2",
      "FY 2026",
      "FY2026",
      "Q2",
      "year-to-date",
      "This Year",
      "2h ago"
    ],
    "financial_terms": [
      "Stock",
      "Earnings",
      "earnings",
      "growth",
      "trading"
    ],
    "financial_metrics": [],
    "market_indicators": [
      "rating"
    ]
  },
  "temporal_analysis": {
    "dates": [
      "Q2 2025",
      "Q2",
      "FY 2026",
      "FY2026",
      "Q2",
      "year-to-date",
      "This Year",
      "2h ago"
    ],
    "time_expressions": [],
    "temporal_relationships": [
      "upcoming"
    ],
    "quarters": [
      "Q2 2025",
      "Q2",
      "Q2"
    ],
    "years": [
      "Q2 2025",
      "FY 2026"
    ],
    "time_periods": []
  },
  "sentiment_analysis": {
    "positive_words": 10,
    "negative_words": 0,
    "positive_ratio": 0.03663003663003663,
    "negative_ratio": 0.0,
    "sentiment_score": 0.03663003663003663,
    "sentiment_label": "positive",
    "sentiment_strength": 0.03663003663003663,
    "confidence": 0.36630036630036633
  },
  "industry_analysis": {
    "dominant_industry": "healthcare",
    "industry_scores": {
      "tech": 1,
      "finance": 1,
      "healthcare": 4,
      "energy": 0,
      "retail": 0,
      "automotive": 0,
      "media": 0,
      "industrial": 0,
      "real_estate": 0,
      "telecom": 0,
      "food_beverage": 0,
      "travel": 0,
      "education": 0,
      "professional": 0,
      "mining": 0,
      "aerospace": 0,
      "environmental": 0,
      "cannabis": 0
    },
    "confidence": 0.6666666666666666
  },
  "market_analysis": {
    "market_sentiment": "bullish",
    "bullish_indicators": 1,
    "bearish_indicators": 0,
    "market_conditions": {
      "volatility": "normal",
      "volume": "normal",
      "trend": "bullish"
    },
    "trading_activity": "normal"
  },
  "competitor_analysis": {
    "companies_mentioned": [
      "Amgen Inc.",
      "AMGN",
      "Amgen",
      "Amgen",
      "William Blair",
      "AMGN",
      "William Blair",
      "Amgen",
      "William Blair",
      "Amgen",
      "William Blair",
      "Amgen",
      "Zacks",
      "Amgen",
      "Amgen",
      "AMGN",
      "Seeking Alpha",
      "Amgen",
      "Amgen",
      "Seeking Alpha",
      "Amgen",
      "Amgen",
      "MSN",
      "Amgen",
      "Zacks",
      "Amgen",
      "Amgen",
      "AMGN",
      "Zacks",
      "AMGN",
      "Amgen Inc.",
      "AMGN",
      "AI Generated"
    ],
    "competitive_context": [
      "William Blair raised its Q2 2025 EPS estimate for AMGN to $5.21 and maintained an “Outperform” rating.",
      "William Blair also boosted its FY 2026 EPS forecast for Amgen to $21.67 while reaffirming an “Outperform” stance."
    ],
    "competitor_count": 33,
    "has_competitive_language": true
  },
  "risk_analysis": {
    "risk_sentences": [
      "Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns\nPositive Sentiment:"
    ],
    "risk_count": 1,
    "risk_level": "low"
  },
  "opportunity_analysis": {
    "opportunity_sentences": [
      "Positive Sentiment:\nAmgen reported that its Phase 3 trial of etelcalcetide in pediatric kidney patients is progressing, potentially expanding its treatment portfolio in a high-need population.",
      "Seeking Alpha notes Amgen’s expanding biosimilars and rare disease pipeline as critical growth drivers to offset upcoming patent expiries."
    ],
    "opportunity_count": 2,
    "opportunity_level": "medium"
  },
  "processing_metadata": {
    "timestamp": "2025-07-17T03:11:57.103664",
    "model_used": "en_core_web_trf",
    "text_length": 1926
  }
}